Obinutuzumab
Showing 26 - 50 of 229
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)
Enrolling by invitation
- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Obinutuzumab
- +6 more
-
Suzhou, Jiangsu, Chinathe First Affiliated Hospital of Soochow University
Mar 22, 2023
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Columbus (Acalabrutinib, Obinutuzumab, Venetoclax)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 2, 2022
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma Trial in
Recruiting
- Ann Arbor Stage II Follicular Lymphoma
- +5 more
- Ibrutinib
- +2 more
-
Fresno, California
- +2 more
Jan 24, 2023
Obinutuzumab in Chinese Real-world Patients With iNHL
Not yet recruiting
- Lymphomas Non-Hodgkin's B-Cell
- Obinutuzumab
-
Changzhou, Jiangsu, China
- +24 more
Jul 23, 2023
Leukemia Trial in Houston (Pirtobrutinib, Obinutuzumab, Venetoclax)
Not yet recruiting
- Leukemia
- Pirtobrutinib
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Sep 7, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Scottsdale, Jacksonville, Rochester (drug, other, biological)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- +4 more
-
Scottsdale, Arizona
- +2 more
Jan 5, 2023
Granulomatosis With Polyangiitis, Microscopic Polyangiitis, ANCA Associated Vasculitis Trial in Boston, Rochester, Philadelphia
Not yet recruiting
- Granulomatosis With Polyangiitis
- +2 more
- Obinutuzumab
- Rituximab
-
Boston, Massachusetts
- +2 more
Dec 29, 2022
Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL) Trial (parsaclisib, rituximab, obinutuzumab)
Withdrawn
- Follicular Lymphoma ( FL)
- Marginal Zone Lymphoma (MZL)
- parsaclisib
- +2 more
- (no location specified)
Jul 14, 2022
Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the National Cancer Institute (NCI) (Venetoclax, Ibrutinib, Prednisone)
Recruiting
- Lymphoma
- +3 more
- Venetoclax
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 20, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Acalabrutinib, Obinutuzumab)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- Obinutuzumab
-
Houston, TexasM D Anderson Cancer Center
Jul 14, 2022
Follicular Lymphoma Trial in Australia (Obinutuzumab 25 MG/1 ML Intravenous Solution, Atezolizumab 1200 MG/40mL Intravenous
Recruiting
- Follicular Lymphoma
- Obinutuzumab 25 MG/1 ML Intravenous Solution
- +2 more
-
Ballarat, Victoria, Australia
- +3 more
Jul 28, 2022
Mantle Cell Lymphoma, Refractory Lymphoma Trial in Boston (Acalabrutinib, Venetoclax, Obinutuzumab)
Recruiting
- Mantle Cell Lymphoma
- Refractory Lymphoma
- Acalabrutinib
- +2 more
-
Boston, Massachusetts
- +1 more
Aug 8, 2022
Marginal Zone Lymphoma Trial in Germany (Obinutuzumab)
Active, not recruiting
- Marginal Zone Lymphoma
- Obinutuzumab
-
Bochum, Germany
- +15 more
Nov 4, 2022
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin Trial in France, Italy, Netherlands (Obinutuzumab, CC-122)
Active, not recruiting
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Non-Hodgkin
- Obinutuzumab
- CC-122
-
Borddeaux Cedex, France
- +9 more
Nov 11, 2022
Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the NCI (obinutuzumab, prednisone, Revlimid)
Recruiting
- Lymphoma
- +3 more
- obinutuzumab
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jul 6, 2022
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in
Recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +3 more
- Acalabrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 17, 2022
Chronic Lymphocytic Leukemia Trial in Milano (Ibrutinib and obinutuzumab)
Recruiting
- Chronic Lymphocytic Leukemia
- Ibrutinib and obinutuzumab
-
Milano, MI, ItalyStrategic Research Program on CLL
Apr 2, 2022
Mantle Cell Lymphoma Trial in Duarte (drug, procedure, biological)
Not yet recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
Sep 20, 2023
Lymphoma Trial in China (Obinutuzumab, Glofitamab, Tocilizumab)
Recruiting
- Lymphoma
- Obinutuzumab
- +2 more
-
Beijing, China
- +6 more
Aug 4, 2022
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL) Trial in United States (Zanubrutinib, Obinutuzumab,
Recruiting
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Leukemia (SLL)
- Zanubrutinib
- +2 more
-
Evanston, Illinois
- +7 more
Sep 9, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in United States (Acalabrutinib, Obinutuzumab)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- Obinutuzumab
-
Basking Ridge, New Jersey
- +7 more
Nov 9, 2022
Chronic Lymphoid Leukemia Trial in Germany (Bendamustine, Obinutuzumab, Acalabrutinib)
Active, not recruiting
- Chronic Lymphoid Leukemia
- Bendamustine
- +3 more
-
Dresden, Germany
- +16 more
Nov 8, 2022
Primary Diffuse Large B-cell Lymphoma of the CNS (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS Trial
Suspended
- Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
- Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
- Obinutuzumab
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jul 6, 2022